Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALXO | ALX Oncology Holdings Inc.

IndexRUT P/E- EPS (ttm)-3.19 Insider Own2.20% Shs Outstand40.88M Perf Week0.20%
Market Cap199.85M Forward P/E- EPS next Y-3.34 Insider Trans-1.52% Shs Float30.36M Perf Month1.62%
Income-130.40M PEG- EPS next Q-0.87 Inst Own99.09% Short Float / Ratio10.40% / 18.42 Perf Quarter-30.37%
Sales- P/S- EPS this Y-46.50% Inst Trans1.32% Short Interest3.16M Perf Half Y4.58%
Book/sh5.20 P/B0.97 EPS next Y-5.70% ROA-45.40% Target Price14.71 Perf Year-54.32%
Cash/sh5.35 P/C0.94 EPS next 5Y- ROE-52.00% 52W Range3.94 - 13.64 Perf YTD-55.46%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-63.20% Beta1.65
Dividend %- Quick Ratio12.50 Sales past 5Y- Gross Margin- 52W Low27.55% ATR0.38
Employees72 Current Ratio12.50 Sales Q/Q- Oper. Margin- RSI (14)50.72 Volatility8.00% 8.35%
OptionableYes Debt/Eq0.04 EPS Q/Q-3.30% Profit Margin- Rel Volume0.76 Prev Close4.82
ShortableYes LT Debt/Eq0.04 EarningsAug 10 AMC Payout- Avg Volume171.38K Price5.02
Recom2.00 SMA205.86% SMA50-6.00% SMA200-28.30% Volume130,845 Change4.15%
Date Action Analyst Rating Change Price Target Change
Dec-22-21Downgrade Jefferies Buy → Hold $65 → $25
Sep-30-21Initiated Stifel Buy $106
May-05-21Resumed Credit Suisse Outperform $98
Apr-26-21Resumed Credit Suisse Outperform $98
Apr-06-21Initiated UBS Buy
Feb-10-21Initiated H.C. Wainwright Buy $100
Aug-11-20Initiated Piper Sandler Overweight $55
Aug-11-20Initiated Jefferies Buy $50
Aug-11-20Initiated Credit Suisse Outperform $53
Aug-11-20Initiated Cantor Fitzgerald Overweight $64
Sep-06-23 08:00AM
Aug-31-23 07:00AM
Aug-14-23 07:31PM
Aug-10-23 04:01PM
07:00AM Loading…
Jun-26-23 07:00AM
May-11-23 04:01PM
May-09-23 07:00AM
Apr-25-23 07:00AM
Apr-19-23 11:36AM
Mar-14-23 08:00AM
Mar-13-23 07:00AM
Mar-09-23 04:01PM
Feb-16-23 07:00AM
Jan-05-23 07:00AM
07:00AM Loading…
Jan-03-23 07:00AM
Dec-12-22 10:00AM
Nov-29-22 07:00AM
Nov-08-22 04:01PM
Nov-03-22 09:00AM
Nov-02-22 07:00AM
Oct-31-22 07:00AM
Oct-05-22 08:01AM
Sep-21-22 04:01PM
Sep-01-22 07:00AM
Aug-16-22 09:45AM
Aug-15-22 07:00AM
Aug-11-22 07:00AM
Aug-08-22 04:01PM
Aug-01-22 07:00AM
08:44AM Loading…
Jun-29-22 08:44AM
Jun-22-22 09:00AM
Jun-03-22 07:00AM
Jun-01-22 07:00AM
Apr-12-22 07:00AM
Mar-02-22 07:00AM
Feb-28-22 07:00AM
Feb-03-22 07:01PM
Feb-02-22 01:38PM
Jan-28-22 12:44PM
Jan-27-22 05:51PM
Jan-19-22 06:23AM
Jan-10-22 06:00AM
Jan-04-22 07:00AM
Dec-14-21 09:00AM
Dec-13-21 01:58PM
Dec-12-21 09:00AM
Nov-11-21 04:05PM
Nov-09-21 11:13AM
Nov-04-21 09:00AM
Nov-02-21 09:00AM
Oct-21-21 11:19AM
Oct-07-21 07:00AM
Oct-01-21 08:00AM
Sep-16-21 07:00AM
Sep-14-21 07:00AM
Sep-07-21 07:00AM
Aug-27-21 06:55AM
Aug-12-21 04:05PM
Jul-28-21 07:00AM
Jul-15-21 12:00PM
Jul-12-21 06:07AM
Jul-06-21 09:15AM
Jul-03-21 07:15AM
Jun-14-21 07:00AM
Jun-10-21 07:00AM
May-18-21 07:00AM
May-17-21 04:05PM
May-10-21 07:00AM
Apr-21-21 04:05PM
Apr-16-21 01:41AM
Apr-05-21 07:00AM
Mar-18-21 04:05PM
Mar-15-21 07:00AM
Mar-05-21 08:15AM
Mar-04-21 04:05PM
Mar-03-21 08:34AM
Mar-02-21 07:00AM
Feb-10-21 10:05AM
Jan-16-21 01:12AM
Jan-11-21 07:00AM
Jan-05-21 07:00AM
Dec-17-20 07:00AM
Dec-14-20 04:05PM
Dec-11-20 10:55PM
Dec-09-20 10:26PM
Dec-07-20 04:08PM
Nov-24-20 07:00AM
Nov-12-20 04:05PM
Nov-09-20 08:10AM
Nov-05-20 07:00AM
Nov-02-20 07:00AM
Oct-28-20 07:00AM
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company's pre-clinical program focuses on the development of ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pinto ShellyVP, Finance and CAOJul 06Sale6.527,34547,88955,713Jul 07 04:09 PM
Pons JaumePresident & CEOJun 30Sale7.343,20823,547536,538Jul 05 05:07 PM
Randolph SophiaChief Medical OfficerJun 30Sale7.341,60511,781281,477Jul 05 05:09 PM
GARCIA PETER SChief Financial OfficerJun 30Sale7.348876,51154,738Jul 05 05:00 PM
Pinto ShellyVP, Finance and CAOJun 30Sale7.344663,42063,058Jul 05 05:05 PM
Randolph SophiaChief Medical OfficerJun 09Option Exercise3.7512,82948,171283,082Jun 13 04:38 PM
Pons JaumePresident & CEODec 29Sale11.073,23235,779539,746Jan 03 08:29 PM
Randolph SophiaChief Medical OfficerDec 29Sale11.071,61717,901270,253Jan 03 08:47 PM
GARCIA PETER SChief Financial OfficerDec 29Sale11.078939,88653,723Jan 03 08:34 PM
Pinto ShellyVP, Finance and CAODec 29Sale11.074825,33662,097Jan 03 08:52 PM
Randolph SophiaChief Medical OfficerDec 16Option Exercise4.0946,474189,875271,870Dec 20 05:08 PM